Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 26
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Contribución de congreso (ConferenceOutput)

MEBAL: A multimodal database for eye blink detection and attention level estimation

  • Daza García, Roberto
  • Morales Moreno, Aythami
  • Fiérrez Aguilar, Julián
  • Tolosana Moranchel, Rubén
© ACM 2020. This is the author's version of the work. It is posted here for your personal use. Not for redistribution. The definitive Version of Record was published in ICMI '20 Companion, October 25–29, 2020, Virtual Event, Netherlands, https://doi.org/10.1145/3395035.3425257, This work presents mEBAL, a multimodal database for eye blink detection and attention level estimation. The eye blink frequency is related to the cognitive activity and automatic detectors of eye blinks have been proposed for many tasks including attention level estimation, analysis of neuro-degenerative diseases, deception recognition, drive fatigue detection, or face anti-spoofing. However, most existing databases and algorithms in this area are limited to experiments involving only a few hundred samples and individual sensors like face cameras. The proposed mEBAL improves previous databases in terms of acquisition sensors and samples. In particular, three different sensors are simultaneously considered: Near Infrared (NIR) and RGB cameras to capture the face gestures and an Electroencephalography (EEG) band to capture the cognitive activity of the user and blinking events. Regarding the size of mEBAL, it comprises 6,000 samples and the corresponding attention level from 38 different students while conducting a number of e-learning tasks of varying difficulty. In addition to presenting mEBAL, we also include preliminary experiments on: i) eye blink detection using Convolutional Neural Networks (CNN) with the facial images, and ii) attention level estimation of the students based on their eye blink frequency, This work has been supported by projects: PRIMA (ITN-2019-860315), TRESPASS-ETN (ITN-2019-860813), IDEA-FAST (IMI2- 2018-15-two-stage-853981), BIBECA (RTI2018-101248-B-I00 MINECOFEDER), and edBB (Universidad Autonoma de Madrid). Ruben Tolosana and postdoc support from CAM/FEDER. Roberto Daza is supported by a PhD FPI fellowship from MINECO-FEDER
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Contribución de congreso (ConferenceOutput)

A Comparative Evaluation of Heart Rate Estimation Methods using Face Videos

  • Hernández Ortega, Javier
  • Diaz, David
  • Fiérrez Aguilar, Julián
  • Morales Moreno, Aythami
© 2020 IEEE.  Personal use of this material is permitted.  Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works, This paper presents a comparative evaluation of methods for remote heart rate estimation using face videos, i.e., given a video sequence of the face as input, methods to process it to obtain a robust estimation of the subject's heart rate at each moment. Four alternatives from the literature are tested, three based in hand-crafted approaches and one based on deep learning. The methods are compared using RGB videos from the COHFACE database. Experiments show that the learning-based method achieves much better accuracy than the hand-crafted ones. The low error rate achieved by the learning-based model makes possible its application in real scenarios, e.g. in medical or sports environments, This work has been supported by projects: IDEAFAST (IMI2-2018-15-two-stage-853981), PRIMA (ITN-2019-860315), TRESPASS-ETN (ITN-2019-860813), BIBECA (RTI2018- 101248-B-I00 MINECO/FEDER), and edBB (UAM). J.H.O. is supported by a PhD Scholarship from UAM. Portions of the research in this paper used the COHFACE Dataset made available by the Idiap Research Institute, Martigny, Switzerland
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Symbolic AI for XAI: Evaluating LFIT inductive programming for explaining biases in machine learning

  • Ortega de la Puente, Alfonso
  • Wang, Zilong
  • de la Cruz, Marina
  • Alonso, César Luis
  • Ribeiro, Tony
  • Fiérrez Aguilar, Julián
  • Morales Moreno, Aythami
Machine learning methods are growing in relevance for biometrics and personal information processing in domains such as forensics, e-health, recruitment, and e-learning. In these domains, white-box (human-readable) explanations of systems built on machine learning methods become crucial. Inductive logic programming (ILP) is a subfield of symbolic AI aimed to automatically learn declarative theories about the processing of data. Learning from interpretation transition (LFIT) is an ILP technique that can learn a propositional logic theory equivalent to a given black-box system (under certain conditions). The present work takes a first step to a general methodology to incorporate accurate declarative explanations to classic machine learning by checking the viability of LFIT in a specific AI application scenario: fair recruitment based on an automatic tool generated with machine learning methods for ranking Curricula Vitae that incorporates soft biometric information (gender and ethnicity). We show the expressiveness of LFIT for this specific problem and propose a scheme that can be applicable to other domains. In order to check the ability to cope with other domains no matter the machine learning paradigm used, we have done a preliminary test of the expressiveness of LFIT, feeding it with a real dataset about adult incomes taken from the US census, in which we consider the income level as a function of the rest of attributes to verify if LFIT can provide logical theory to support and explain to what extent higher incomes are biased by gender and ethnicity, This work was supported by projects: PRIMA (H2020-MSCA-ITN-2019-860315), TRESPASS-ETN(H2020-MSCA-ITN-2019-860813), IDEA-FAST (IMI2-2018-15-853981), BIBECA(RTI2018-101248-B-I00MINECO/FEDER), RTI2018-095232-B-C22MINECO, PLeNTaS project PID2019-111430RBI00MINECO; and also by Pays de la Loire Region through RFI Atlanstic 2020
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

  • Kirk, Cameron
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mobilise-D consortium
This study aimed to validate a wearable device's walking speed estimation pipeline, considering complexity, speed, and walking bout duration. The goal was to provide recommendations on the use of wearable devices for real-world mobility analysis. Participants with Parkinson's Disease, Multiple Sclerosis, Proximal Femoral Fracture, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, and healthy older adults (n = 97) were monitored in the laboratory and the real-world (2.5 h), using a lower back wearable device. Two walking speed estimation pipelines were validated across 4408/1298 (2.5 h/laboratory) detected walking bouts, compared to 4620/1365 bouts detected by a multi-sensor reference system. In the laboratory, the mean absolute error (MAE) and mean relative error (MRE) for walking speed estimation ranged from 0.06 to 0.12 m/s and - 2.1 to 14.4%, with ICCs (Intraclass correlation coefficients) between good (0.79) and excellent (0.91). Real-world MAE ranged from 0.09 to 0.13, MARE from 1.3 to 22.7%, with ICCs indicating moderate (0.57) to good (0.88) agreement. Lower errors were observed for cohorts without major gait impairments, less complex tasks, and longer walking bouts. The analytical pipelines demonstrated moderate to good accuracy in estimating walking speed. Accuracy depended on confounding factors, emphasizing the need for robust technical validation before clinical application.Trial registration: ISRCTN - 12246987., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD, LR, AY were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST—Grant Agreement 853981. LA, LR, AY and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. LA, LR, AY and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the National Institute for Health Research (NIHR) through the Sheffield Biomedical Research Centre (BRC, Grant Number IS-BRC-1215–20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and from the Generalitat de Catalunya through the CERCA Program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, NHS, NIHR, DHSC, or any associated partners are responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Construct validity of real-world digital mobility outcomes in patients after proximal femoral fracture: a cross-sectional observational study

  • Eckert, Tobias
  • de las Heras, Martí
  • Alvarez, Paula
  • Buekers, Joren
  • Koch, Sarah
  • García Aymerich, Judith
Digital mobility outcomes (DMOs) offer unique insights into recovery of real-world mobility after proximal femoral fracture (PFF), but their clinical validity remains to be established. This study assessed construct validity (convergent, divergent, and known-groups) of 24 DMOs measuring walking activity (amount, pattern) and gait (pace, rhythm, bout-to-bout variability) in patients within one year after PFF. Patients were recruited from inpatient and outpatient lists at five European sites, resulting in 505 included participants (66% female), with mean age of 77.6 ± 9.4 years and supervised gait speed of 0.7 ± 0.4 m/s. Mobility was monitored over seven days using a single wearable device on the lower back. Convergent and divergent validity analyses were stratified by two groups: acute (≤ 14 days since surgery) and non-acute (≥ 15 days since surgery). Correlations between DMOs and related (clinical- and patient-reported mobility outcomes) and unrelated constructs (hearing impairment and systolic blood pressure) were compared to a priori expected correlations. Known-groups validity was assessed across four recovery phases. The results were evaluated individually by experts and in a subsequent consensus meeting, with 17 of 24 DMOs showing evidence of construct validity in non-acute PFF patients. These findings represent an initial step in a larger process towards regulatory endorsement., This study is part of the Mobilise-D project, which was funded by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU received support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This work was also supported by the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre (NIHR203321). ISGlobal acknowledges support from the grant CEX2023-0001290-S funded by MCIN/AEI/ https://doi.org/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. MdlH was funded by European Union-NextGenerationEU, under the Program Investigo (INVESTIGO 2022, AGAUR- ref. BDNS 608313, file 2022 INV-1 00046 - Code 100046TC19). LR is supported by the IMI2 JU project IDEA-FAST (grant agreement 853981). LR is supported by the NIHR Newcastle Biomedical Research Centre based at The Newcastle upon Tyne Hospital National Health Service (NHS) Foundation Trust, Newcastle University, and the Cumbria, Northumberland, and Tyne and Wear NHS Foundation Trust and the NIHR/Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. LR received funding from the NIHR Senior Investigator Awards (2020-2024 and 2024-2028). Content in this publication reflects the authors¿ views and neither IMI nor the European Union, EFPIA, NHS, NIHR or the Department of Health and Social Care are responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cocreating the visualization of digital mobility outcomes: Delphi-type process with patients

  • Lumsdon, Jack
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Cantu, Alma
Background: Recent technological advances in wearable devices offer new potential for measuring mobility in real-world contexts. Mobilise-D has validated digital mobility outcomes to provide novel outcomes and end points in clinical research of 4 different long-term health conditions (Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, and proximal femoral fracture). These outcomes also provide unique information that is important to patients; however, there is limited literature that explores the optimal methods to achieve this, such as the best way to visualize patients' data. Objective: This study aimed to identify meaningful outcomes for each condition and how to best visualize them from the perspective of end users. Methods: Using a Delphi-type protocol with patients as subject matter experts, we gathered iterative feedback on the cocreation of visualizations through 3 rounds of questionnaires. An open-ended questionnaire was used in round 1 to understand what aspects of mobility were most influenced by their health condition. These responses were mapped onto relevant digital mobility outcomes and walking experiences and then prioritized for visualization. Using patient responses, we worked alongside researchers, clinicians, and a patient advisory group to develop visualizations that depicted a week of mobility data. During rounds 2 and 3, participants rated usefulness and ease of understanding on a 5-point Likert scale and provided unstructured feedback in comment boxes for each visualization. Visualizations were refined using the feedback from round 2 before receiving further feedback in round 3. Results: Participation varied across rounds 1 to 3 (n=48, n=79, and n=78, respectively). Round 1 identified important outcomes and contexts for each health condition, such as walking speed and stride length for people with Parkinson disease or multiple sclerosis and number of steps for people with chronic obstructive pulmonary disease or proximal femoral fracture. The consensus was not reached for any visualization reviewed in round 2 or 3. Feedback was generally positive, and some participants reported that they were able to understand the visualization and interpret what the visualization represented. Conclusions: Through the feedback provided and existing data visualization principles, we developed recommendations for future visualizations of mobility- and health-related data. Visualizations should be readable by ensuring that large and clear fonts are used and should be friendly for people with vision impairments, such as color blindness. Patients have a strong understanding of their own condition and its variability; hence, adding additional factors into visualizations is recommended to better reflect the nuances of a condition. Ensuring that outcomes and visualizations are meaningful requires close collaboration with patients throughout the development process., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU; grant agreement 820820). This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The content of the current publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, nor any associated partners are responsible for any use that may be made of the information contained herein. HG was supported by the Fraunhofer Internal Programs (grants Attract 044–602140 and 044–602150). HG also received institutional funding from the Deutsche Forschungsgemeinschaft (German Research Foundation)—SFB 1483—Project-ID 442419336, EmpkinS. LR, AY, and SDD were also supported by the IMI2 JU project IDEA-FAST (grant agreement 853981). LR, AY, and SDD were supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre based at The Newcastle upon Tyne Hospital National Health Service (NHS) Foundation Trust, Newcastle University, and the Cumbria, Northumberland, and Tyne and Wear NHS Foundation Trust and the NIHR/Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. LR received funding from the NIHR Senior Investigator Awards (2020-2024 and 2024-2028). EB was supported by the NIHR Sheffield Biomedical-Research Centre and Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the Department of Health and Social Care.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Laboratory and free-living gait performance in adults with COPD and healthy controls

  • Buekers, Joren
  • Koch, Sarah
  • García Aymerich, Judith
Background: Gait characteristics are important risk factors for falls, hospitalisations and mortality in older adults, but the impact of COPD on gait performance remains unclear. We aimed to identify differences in gait characteristics between adults with COPD and healthy age-matched controls during 1) laboratory tests that included complex movements and obstacles, 2) simulated daily-life activities (supervised) and 3) free-living daily-life activities (unsupervised). Methods: This case-control study used a multi-sensor wearable system (INDIP) to obtain seven gait characteristics for each walking bout performed by adults with mild-to-severe COPD (n=17; forced expiratory volume in 1 s 57±19% predicted) and controls (n=20) during laboratory tests, and during simulated and free-living daily-life activities. Gait characteristics were compared between adults with COPD and healthy controls for all walking bouts combined, and for shorter (≤30 s) and longer (>30 s) walking bouts separately. Results: Slower walking speed (-11 cm·s-1, 95% CI: -20 to -3) and lower cadence (-6.6 steps·min-1, 95% CI: -12.3 to -0.9) were recorded in adults with COPD compared to healthy controls during longer (>30 s) free-living walking bouts, but not during shorter (≤30 s) walking bouts in either laboratory or free-living settings. Double support duration and gait variability measures were generally comparable between the two groups. Conclusion: Gait impairment of adults with mild-to-severe COPD mainly manifests during relatively long walking bouts (>30 s) in free-living conditions. Future research should determine the underlying mechanism(s) of this impairment to facilitate the development of interventions that can improve free-living gait performance in adults with COPD., Support statement: This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 820820. This JU receives support from the European Union's Horizon 2020 research and innovation programme, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). S. Del Din and L. Rochester were also supported by the Innovative Medicines Initiative 2 (IMI2) JU project IDEA-FAST – grant agreement 853981. S. Del Din, L. Alcock and L. Rochester were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust, and by the NIHR/Welcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. C. Mazzà and E. Buckley were also supported by the Sheffield BRC based at the Sheffield Teaching Hospital and the University of Sheffield. H. Demeyer is a post-doctoral research fellow of the Flemish Research Foundation (FWO Flanders). The Barcelona Institute for Global Health (ISGlobal) receives support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” Programme (CEX 2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Programme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, the IMI, the European Union, the EFPIA or any Associated Partners. Funding information for this article has been deposited with the Crossref Funder Registry.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Digital assessment of real-world walking in people with impaired mobility: How many hours and days are needed?

  • Buekers, Joren
  • Koch, Sarah
  • Marchena, José
  • Lemos, Jorge
  • García Aymerich, Judith
Background: Impaired mobility increases falls and mortality risk. However, guidelines to reliably assess real-world walking activity and gait remain undefined. We aimed to (i) determine the minimum daily wear time during waking hours (7:00–22:00) for a valid measurement day, (ii) identify the minimum number of valid days, and (iii) weekend days, to reliably assess weekly walking activity and gait parameters, and (iv) provide recommendations for reliable real-world walking assessments. Methods: Participants with chronic obstructive pulmonary disease (n = 565), multiple sclerosis (n = 558), Parkinson’s disease (n = 543) or proximal femoral fracture (n = 487) from 10 countries were asked to wear a single wearable device on the lower back, 24 h/day for seven days, resulting in 13,191 measurement days. The Mobilise-D processing pipeline was used to obtain 24 daily walking activity and gait parameters. Minimum daily wear time was determined as the highest wear time category that did not statistically change parameter values. Intraclass correlation coefficients ≥ 0.80 determined the minimum number of valid measurement and weekend days. Results: The minimum daily wear time varied between “no requirement” (13% of parameter-condition combinations) and > 14 h (19%), with higher requirements for walking activity than gait parameters. The minimum number of days ranged from 1 (17%) to > 7 days (6%), and was higher for parameters that are yet to be clinically validated. There was no evidence of a weekend nor health condition effect on parameter reliability. Conclusions: For studies involving multiple walking activity and gait parameters or health conditions, expert consensus recommends a minimum of > 12 h of daily wear time across ≥ 3 days. For studies that involve specific parameters or health conditions, individual recommendations are provided within the manuscript. Supplementary Information: The online version contains supplementary material available at 10.1186/s12966-025-01851-3., This work was supported by the Mobilise-D project that received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Barcelona Institute for Global Health (ISGlobal) receives support from the grant CEX2023-0001290-S funded by MCIN/AEI/https://doi.org/10.13039/5011 00011033, and support from the Generalitat de Catalunya through the CERCA rogram. Joren Buekers (FJC2021-046458-I) and Sarah Koch (IJC2020-044363-I) received funding from the Juan de la Cierva Formación and Incorporación, respectively, financed by MICIU/AEI/https://doi.org/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. This paper presents independent research supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC), and the NIHR Sheffield BRC. The NIHR Newcastle BRC is a partnership between Newcastle Hospitals NHS Foundation Trust, Newcastle University, and Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust and is funded by the NIHR. The research was also supported by the NIHR Sheffield Biomedical Research Centre based at the Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield and carried out at the NIHR Sheffield Clinical Research Facility at the Sheffield Teaching Hospitals NHS Foundation Trust. LR, AY and SDD were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST - Grant Agreement 853981. LR, AY and SDD were supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust and, the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. SDD was supported by the UK Research and Innovation (UKRI) Engineering and Physical Sciences Research Council (EPSRC) (Grant Ref: EP/W031590/1, Grant Ref: EP/X031012/1 and Grant Ref: EP/X036146/1). AY is also supported by the Michael J Fox Foundation (grant references MJFF-022735 & MJFF-022737), UK Engineering and Physical Sciences Research Council (EPSRC), grant number EP/X036146/1, Intercept Pharmaceuticals, NIHR HTA (grant reference NIHR129175). She is in receipt of grants from Parkinson's UK, Weston Brain Institute, Dunhill Medical Trust and Cure Parkinson's Trust. HD is a post-doctoral researcher of FWO Flanders (12ZW822N). The views expressed are those of the authors and not necessarily those of the IMI, the European Union, the EFPIA, NHS, NIHR, the Department of Health and Social Care or any Associated Partners
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Digital mobility outcomes to describe real-world walking during recovery from a hip fracture: the Mobilise-D perspective

  • Becker, Clemens
  • García Aymerich, Judith
  • Delgado-Ortiz, Laura
  • Koch, Sarah
  • Buekers, Joren
  • Alvarez, Paula
  • Marcuzzi, Anna
Purpose: The burden of disease caused by fragility fractures, and hip fractures in particular, is significant both from a personal and a societal perspective. Digital technologies such as wearable devices now allow a real-world assessment of walking and physical mobility, describing temporal and spatial measures. Built on a transparent technical validation, the Mobilise-D consortium validated a set of digital mobility outcomes (DMOs) alongside a longitudinal clinical validation study (CVS). This article provides a description of DMOs along with supervised mobility assessment and patient-reported outcomes collected at entry of the CVS study in a sample of home-dwelling participants with a proximal femoral fracture (PFF) recruited within 1 year after surgery. Methods: Participants who underwent surgical treatment for a low-energy PFF were recruited from five sites in three high-income European countries. The first visit encompassed a clinical assessment (~ 3 h) and subsequent 7-day measurement of real-world mobility with a single wearable device. We categorized participants into four recovery phases according to the assessment time after surgery: acute phase (≤ 14 days after surgery, hospital stay), post-acute phase (15-42 days after surgery, mostly rehabilitation), extended recovery phase (43-182 days post-surgery, typically post-discharge at home), and long-term recovery phase (183-365 days post-surgery). All variables were reported descriptively for each phase using mean and standard deviation or median and 25th-75th percentile depending on their distribution. Results: We enrolled 564 PFF participants (66% women). The mean age was 77.5 (SD 9.6) years. Almost 90% of all participants (n = 505) had a valid digital mobility assessment (wear time of > 12 h per day and at least 3 valid days). DMO domains such as amount (e.g., number of steps), pace (e.g., walking speed), and pattern (bout distribution) demonstrated large differences across phases. Conclusions: The observed variation in walking amount and pace and pattern across recovery phases indicate that DMOs provide a granular analysis of real-world mobility of hip fracture survivors. When confirmed by longitudinal analyses, including results on minimal important differences, the use of selected DMOs will provide a novel approach for monitoring, predictive modelling, prognosis, stratification, and evaluation of clinical trials and hip fracture services., Open Access funding enabled and organized by Projekt DEAL. This study was part of the Mobilise-D project, which was funded by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD and LR were also supported by the IDEA-FAST project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853981.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Walking into aging: real-world mobility patterns and digital benchmarks from the InCHIANTI Study

  • Albites-Sanabria, Jose
  • Palumbo, Pierpaolo
  • Bandinelli, Stefania
  • D'Ascanio, Ilaria
  • Mellone, Sabato
  • Paraschiv-Ionescu, Anisoara
  • Küderle, Arne
  • Cereatti, Andrea
  • Del Din, Silvia
  • Kluge, Felix
  • Gazit, Eran
  • Jansen, Carl-Philipp
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Rochester, Lynn
  • Klenk, Jochen
  • Ferrucci, Luigi
  • Becker, Clemens
  • Chiari, Lorenzo
  • Palmerini, Luca
Mobility is a cornerstone of health and quality of life, particularly in older adults. Digital mobility outcomes (DMOs) from real-world walking data offer crucial insights into the functional status and early markers of mobility decline. This study provides reference values for walking activity, pace, rhythm, and gait bout-to-bout variability in community-dwelling older adults and evaluates the effects of age, sex, height, and weight on these parameters. Using data from 200 older adults (aged 65-94 years) from the InCHIANTI Study and applying the Mobilise-D computational pipeline, we analyzed real-world walking over a week. Significant differences by sex and age were found, with males showing higher walking activity in younger age groups (65-74 and 75-84 years) but not in the oldest group (85-94 years). Additionally, we observed non-linear trends in mobility metrics with age, indicating an accelerated reduction in mobility at certain age ranges. These findings underscore the importance of monitoring real-world walking data to pinpoint critical periods of mobility decline and guide targeted interventions. This work offers valuable benchmarks for clinical assessments and future research., We want to acknowledge the participants who volunteered to take part in the clinical studies. Their contribution has been vital to the successful completion of the present study. The InCHIANTI baseline study (1998–2000) was supported as a “targeted project” (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336); the InCHIANTI follow-up study 1 (2001–2003) was funded by the U.S. National Institute on Aging (Contracts: N.1-AG[1]1-1 and N.1-AG-1-2111); the InCHIANTI follow-up study 4 and 5 were supported by the Agency for Regional Health Care of Tuscany (Reg. n° 586/R, 26/10/2012). This research was co-funded by the Italian Complementary National Plan PNC-I.1 Research initiatives for innovative technologies and pathways in the health and welfare sector” D.D. 931 of 06/06/2022, DARE - DigitAl lifelong pRevEntion initiative, code PNC0000002, CUP: B53C22006450001. The study has been funded in part by the European Union (Seventh Framework Program (FP7/2007-2013) under grant agreement No.: 288940 (FARSEEING project)), and by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820820 (Mobilise[1]D). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. S.D.D. was also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST - Grant Agreement 853981 and by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. S.D.D. was supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. S.D.D. was also supported by the UK Research and Innovation (UKRI) Engineering and Physical Sciences Research Council (EPSRC) (Grant Ref: EP/W031590/1, Grant Ref: EP/X031012/1 and Grant Ref: EP/X036146/1).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform

  • Palmqvist, Sebastian
  • Anastasi, Federica
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, José
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden (n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93-0.96. In secondary care, the accuracies were 89-91%, the positive predictive values 89-95% and the negative predictive values 77-90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92-94% in secondary and primary care, excluding 12-17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations., We would like to express our gratitude to the participants, and relatives, in all studies, without whom this research would have not been possible. In addition, we thank B. Arslan for analyzing plasma Aβ in the Gothenburg cohort. The BioFINDER group was supported by the National Institute of Aging (grant no. R01AG083740 to O.H., S.P., R.O. and S.J.), Alzheimer’s Association (grant nos. SG-23-1061717 and ZEN24-1069572 to O.H.), GHR Foundation (O.H. and S.P.), European Research Council (ERC, grant no. ADG-101096455 to O.H.), Swedish Research Council (grant nos. 2023-00356 to O.H., 2021-02219 to N.M.-C. and 2018-02052 to S.P.), ERA PerMed (grant no. ERAPERMED2021-184 to O.H.), the Knut and Alice Wallenberg Foundation (grant no. 2022-0231 to O.H.), the European Union’s (EU’s) Horizon Europe research and innovation program under grant agreement no. 101053962 (to O.H.), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University (to O.H.), the Swedish Alzheimer Foundation (grant nos. AF-1011949 and AF-994075 to S.P., AF-994229 to N.M.-C. and AF-981132 to S.P.), the Swedish Brain Foundation (grant nos. FO2023-0163 to N.M.-C., FO2024-0284 and FO2022-0204 to S.P. and FO2021-0293 to O.H.), the family Rönström’s Foundation (grant nos. FRS-0003 to N.M.-C. and FRS-0004 and FRS-0011 to S.P.), the Berg Family Foundation (O.H.), the Parkinson Foundation of Sweden (grant no. 1412/22 to O.H.), the Cure Alzheimer’s fund (O.H.), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (O.H.), the Skåne University Hospital Foundation (grant no. 2020-O000028 to S.P.), EU Joint Programme Neurodegenerative Diseases (grant no. 2019-03401 to N.M.-C.), WASP and DDLS Joint call for research projects (grant no. WASP/DDLS22-066 to N.M.-C.), Regionalt Forskningsstöd (grant no. 2022-1346 to S.P.) and the Swedish Federal Government under the ALF-agreement (grant nos. 2022-Projekt0107 to N.M.-C., 2022-Projekt0080 to O.H. and 2018-Projekt0226 to S.P.). The precursor of [18F]flutemetamol was sponsored by GE Healthcare. For the Gothenburg group, S.K. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (nos. ALFGBG-1005471, ALFGBG-965923, ALFGBG-81392 and ALFGBG-771071), the Alzheimerfonden (grant nos. AF-842471, AF-737641, AF-929959 and AF-939825), the Swedish Research Council (grant nos. 2019-02075 and 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden and the Swedish Brain Foundation (grant no. FO2024-0097). A.D. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant no. ALFGBG-984092). H.Z. is a Wallenberg Scholar and a distinguished professor at the Swedish Research Council. K.B. is supported by the Swedish Research Council (grant nos. 2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (grant nos. AF-930351, AF-939721, AF-968270 and AF-994551), Hjärnfonden, Sweden (grant nos. ALZ2022-0006, FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant nos. ALFGBG-965240 and ALFGBG-1006418), the Alzheimer’s Association 2022–2025 (grant no. SG-23-1038904 QC), the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden and an anonymous philanthropist and donor. The Barcelona group thanks P. Ortiz-Romero, M. de Diego, E. Jiménez, J. Torres and M. del Campo for technical support. F.A. received funding from grant no. JDC2022-049347-I, funded by the MCIU/AEI/10.13039/501100011033 and the EU NextGeneration EU/PRTR. M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001; project PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)). For the Brescia group, A. Pilotto has beensupported by grants of Airalzh Foundation AGYR2021) Life-BIO grant, the LIMPE-DISMOV Foundation Segala Grant 2021, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. V.Q. was supported by the H2020 IMI IDEA-FAST (grant no. ID853981). C.T. was supported by the PRIN 2021 RePlast (grant no. 20202THZAW). A. Padovani has been supported by grants of the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209, RF-2019 RF-2019-12369272 and PNRR-Health PNRR-MAD-2022-12376110. The funders had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review or approval of the paper and decision to submit the paper for publication.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Evaluating the accuracy and reliability of real-world digital mobility outcomes in older adults after hip fracture: Cross-sectional observational study

  • Berge, Martin A.
  • García Aymerich, Judith
  • Koch, Sarah
  • Vereijken, Beatrix
Background: Algorithms estimating real-world digital mobility outcomes (DMOs) are increasingly validated in healthy adults and various disease cohorts. However, their accuracy and reliability in older adults after hip fracture, who often walk slowly for short durations, is underexplored. Objective: This study examined DMO accuracy and reliability in a hip fracture cohort considering walking bout (WB) duration, physical function, days since surgery, and walking aid use. Methods: In total, 19 community-dwelling participants were real-world monitored for 2.5 hours using a lower back wearable device and a reference system combining inertial modules, distance sensors, and pressure insoles. A total of 6 DMO estimates from 164 WBs from 58% (11/19) of the participants (aged 71-90 years; assessed 32-390 days after surgery; Short Physical Performance Battery [SPPB] scores of 3-12; gait speed range 0.39-1.34 m/s) were assessed against the reference system at the WB and participant level. We stratified by WB duration (all WBs, WBs of >10 seconds, WBs of 10-30 seconds, and WBs of >30 seconds) and lower versus higher SPPB scores and observed whether days since surgery and walking aid use affected DMO accuracy and reliability. Results: Across WBs, walking speed and distance ranged from 0.25 to 1.29 m/s and from 1.7 to 436.5 m, respectively. Estimation of walking speed, cadence, stride duration, number of steps, and distance stratified by WB duration showed intraclass correlation coefficients (ICCs) ranging from 0.50 to 0.99 and mean relative errors (MREs) from -6.9% to 12.8%. Stride length estimation showed poor reliability, with ICCs ranging from 0.30 to 0.49 and MREs from 6.1% to 13.2%. Walking speed and distance ICCs in the higher-SPPB score group ranged from 0.85 to 0.99, and MREs ranged from -10.1% to -1.7%. In the lower-SPPB score group, walking speed and distance ICCs ranged from 0.17 to 0.99, and MREs ranged from 13.5% to 32.6%. There was no discernible effect of time since surgery or walking aid use. Conclusions: In total, 5 accurate and reliable real-world DMOs were identified in older adults after hip fracture: walking speed, cadence, stride duration, number of steps, and distance. Accuracy and reliability of most DMOs improved when excluding WBs of <10 seconds and were higher for WBs of >30 seconds than for WBs of 10 to 30 seconds and for participants with higher physical function. DMOs capture daily gait as early as 1 month after surgery also in people using walking aids. However, as most WBs in this cohort were short, there was a trade-off between improving accuracy and reliability by excluding short WBs and losing a substantial amount of data. These results have important implications for establishing the clinical validity of DMOs and evaluating the effects of interventions on daily-life gait, thereby facilitating the design of optimal care pathways., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. The authors thank the Mobilise-D technical validation study team of work package 2, all participants who devoted their time and energy to this taxing protocol in times of COVID-19, and Miriam Dinger at the Robert Bosch Foundation for Medical Research and Dr Tim Klüter at University Hospital Schleswig-Holstein for their indispensable help in recruiting patients. MAB acknowledges ChatGPT, an artificial intelligence model by OpenAI, for suggestions that helped improve the clarity of some sentences in this paper. SDD and LR were also supported by the Identifying Digital Endpoints to Assess Fatigue, Sleep, and Activities in Daily Living in Neurodegenerative Disorders and Immune-Mediated Inflammatory Diseases project that has received funding from the IMI 2 Joint Undertaking under grant agreement 853981. LR is a National Institute for Health and Care Research (NIHR) senior investigator. Both SDD and LR were supported by the NIHR Newcastle Biomedical Research Centre based at the Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust; Newcastle University; and the Cumbria, Northumberland, Tyne, and Wear NHS Foundation Trust. SDD and LR were also supported by the NIHR and Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. SDD was supported by the UK Research and Innovation Engineering and Physical Sciences Research Council (grant reference EP/X031012/1 and EP/X036146/1). The Barcelona Institute for Global Health acknowledges support from grant CEX2018-000806-S funded by the Ministry of Science, Innovation, and Universities and the State Research Agency (MCIN/AEI/10.13039/501100011033) and support from the Government of Catalonia through the Research Centers of Catalonia program. The views expressed in this publication are those of the authors and do not necessarily reflect those of the IMI, the European Union, the European Federation of Pharmaceutical Industries and Associations, any associated partners, the NIHR, or the Department of Health and Social Care, who are not responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Real-World gait detection using a wrist-worn inertial sensor: Validation study

  • Kluge, Felix
  • Buekers, Joren
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mueller, Arne
Background: Wrist-worn inertial sensors are used in digital health for evaluating mobility in real-world environments. Preceding the estimation of spatiotemporal gait parameters within long-term recordings, gait detection is an important step to identify regions of interest where gait occurs, which requires robust algorithms due to the complexity of arm movements. While algorithms exist for other sensor positions, a comparative validation of algorithms applied to the wrist position on real-world data sets across different disease populations is missing. Furthermore, gait detection performance differences between the wrist and lower back position have not yet been explored but could yield valuable information regarding sensor position choice in clinical studies. Objective: The aim of this study was to validate gait sequence (GS) detection algorithms developed for the wrist position against reference data acquired in a real-world context. In addition, this study aimed to compare the performance of algorithms applied to the wrist position to those applied to lower back-worn inertial sensors. Methods: Participants with Parkinson disease, multiple sclerosis, proximal femoral fracture (hip fracture recovery), chronic obstructive pulmonary disease, and congestive heart failure and healthy older adults (N=83) were monitored for 2.5 hours in the real-world using inertial sensors on the wrist, lower back, and feet including pressure insoles and infrared distance sensors as reference. In total, 10 algorithms for wrist-based gait detection were validated against a multisensor reference system and compared to gait detection performance using lower back-worn inertial sensors. Results: The best-performing GS detection algorithm for the wrist showed a mean (per disease group) sensitivity ranging between 0.55 (SD 0.29) and 0.81 (SD 0.09) and a mean (per disease group) specificity ranging between 0.95 (SD 0.06) and 0.98 (SD 0.02). The mean relative absolute error of estimated walking time ranged between 8.9% (SD 7.1%) and 32.7% (SD 19.2%) per disease group for this algorithm as compared to the reference system. Gait detection performance from the best algorithm applied to the wrist inertial sensors was lower than for the best algorithms applied to the lower back, which yielded mean sensitivity between 0.71 (SD 0.12) and 0.91 (SD 0.04), mean specificity between 0.96 (SD 0.03) and 0.99 (SD 0.01), and a mean relative absolute error of estimated walking time between 6.3% (SD 5.4%) and 23.5% (SD 13%). Performance was lower in disease groups with major gait impairments (eg, patients recovering from hip fracture) and for patients using bilateral walking aids. Conclusions: Algorithms applied to the wrist position can detect GSs with high performance in real-world environments. Those periods of interest in real-world recordings can facilitate gait parameter extraction and allow the quantification of gait duration distribution in everyday life. Our findings allow taking informed decisions on alternative positions for gait recording in clinical studies and public health. Trial registration: ISRCTN Registry 12246987; https://www.isrctn.com/ISRCTN12246987. International registered report identifier (irrid): RR2-10.1136/bmjopen-2021-050785., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU; grant 820820). The IMI2 JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. SDD, LR, and AY were also supported by the IMI2 JU project Identifying Digital Endpoints to Assess Fatigue, Sleep and Activities in Daily Living (grant 853981). LA, LR, AY, and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust. JMH and YEB are supported in part by the National Institutes of Health (grant R01AG79133). LA, LR, AY, and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility infrastructure at The Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the NIHR through the Sheffield BRC (grant IS-BRC-1215-20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” program (CEX2018-000806-S) and from the Generalitat de Catalunya through the Centres de Recerca de Catalunya program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither Innovative Medicines Initiative nor the European Union, European Federation of Pharmaceutical Industries and Associations, National Health Service, NIHR, Department of Health and Social Care, or any associated partners are responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Assessing real-world gait with digital technology? Validation, insights and recommendations from the Mobilise-D consortium

  • Micó-Amigo, M. Encarna
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mobilise-D consortium
Background: Although digital mobility outcomes (DMOs) can be readily calculated from real-world data collected with wearable devices and ad-hoc algorithms, technical validation is still required. The aim of this paper is to comparatively assess and validate DMOs estimated using real-world gait data from six different cohorts, focusing on gait sequence detection, foot initial contact detection (ICD), cadence (CAD) and stride length (SL) estimates. Methods: Twenty healthy older adults, 20 people with Parkinson's disease, 20 with multiple sclerosis, 19 with proximal femoral fracture, 17 with chronic obstructive pulmonary disease and 12 with congestive heart failure were monitored for 2.5 h in the real-world, using a single wearable device worn on the lower back. A reference system combining inertial modules with distance sensors and pressure insoles was used for comparison of DMOs from the single wearable device. We assessed and validated three algorithms for gait sequence detection, four for ICD, three for CAD and four for SL by concurrently comparing their performances (e.g., accuracy, specificity, sensitivity, absolute and relative errors). Additionally, the effects of walking bout (WB) speed and duration on algorithm performance were investigated. Results: We identified two cohort-specific top performing algorithms for gait sequence detection and CAD, and a single best for ICD and SL. Best gait sequence detection algorithms showed good performances (sensitivity > 0.73, positive predictive values > 0.75, specificity > 0.95, accuracy > 0.94). ICD and CAD algorithms presented excellent results, with sensitivity > 0.79, positive predictive values > 0.89 and relative errors < 11% for ICD and < 8.5% for CAD. The best identified SL algorithm showed lower performances than other DMOs (absolute error < 0.21 m). Lower performances across all DMOs were found for the cohort with most severe gait impairments (proximal femoral fracture). Algorithms' performances were lower for short walking bouts; slower gait speeds (< 0.5 m/s) resulted in reduced performance of the CAD and SL algorithms. Conclusions: Overall, the identified algorithms enabled a robust estimation of key DMOs. Our findings showed that the choice of algorithm for estimation of gait sequence detection and CAD should be cohort-specific (e.g., slow walkers and with gait impairments). Short walking bout length and slow walking speed worsened algorithms' performances. Trial registration ISRCTN - 12246987., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant Agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD, LR, AY were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST—Grant Agreement 853981. LA, LR, AY and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. LA, LR, AY and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the National Institute for Health Research (NIHR) through the Sheffield Biomedical Research Centre (BRC, Grant Number IS-BRC-1215–20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and from the Generalitat de Catalunya through the CERCA Program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, NHS, NIHR, DHSC, or any associated partners are responsible for any use that may be made of the information contained herein.
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Reseña (Review)

ECG biometric recognition: Review, system proposal, and benchmark evaluation

  • Melzi, Pietro
  • Vera Rodríguez, Rubén
  • Tolosana Moranchel, Rubén
ECGs have shown unique patterns to distinguish between different subjects and present important advantages compared to other biometric traits. However, the lack of public data and standard experimental protocols makes the evaluation and comparison of novel ECG methods difficult. In this study, we perform extensive analysis and comparison of different scenarios in ECG biometric recognition. We consider verification and identification tasks, single- and multi-session settings, and single- and multi-lead ECGs recorded with traditional and user-friendly devices. We also present ECGXtractor, a robust Deep Learning technology trained with an in-house large-scale database, and evaluate it with detailed experimental protocol and public databases. With the popular PTB database, we achieve Equal Error Rates of 0.14% and 2.06% in single- and multi-session verification. The results achieved prove the soundness of ECGXtractor across multiple scenarios and databases. We release the source code, experimental protocol details, and pre-trained models in GitHub to advance in the field, This work was supported in part by the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Grant under Agreement 860813-TRESPASS-ETN and Agreement 860315-PRIMA-ITN; in part by the IDEA-FAST under Grant IMI2-2018-15-853981; and in part by INTER-ACTION, Ministerio de Ciencia e Innovación (MICINN)/Fondo Europeo de Desarrollo Regional (FEDER), under Grant PID2021-126521OB-I00
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Digital mobility outcomes to describe real-world walking during recovery from a hip fracture: the Mobilise-D perspective

  • Becker, Clemens
  • García Aymerich, Judith
  • Delgado-Ortiz, Laura
  • Koch, Sarah
  • Buekers, Joren
  • Alvarez, Paula
  • Marcuzzi, Anna
Purpose: The burden of disease caused by fragility fractures, and hip fractures in particular, is significant both from a personal and a societal perspective. Digital technologies such as wearable devices now allow a real-world assessment of walking and physical mobility, describing temporal and spatial measures. Built on a transparent technical validation, the Mobilise-D consortium validated a set of digital mobility outcomes (DMOs) alongside a longitudinal clinical validation study (CVS). This article provides a description of DMOs along with supervised mobility assessment and patient-reported outcomes collected at entry of the CVS study in a sample of home-dwelling participants with a proximal femoral fracture (PFF) recruited within 1 year after surgery. Methods: Participants who underwent surgical treatment for a low-energy PFF were recruited from five sites in three high-income European countries. The first visit encompassed a clinical assessment (~ 3 h) and subsequent 7-day measurement of real-world mobility with a single wearable device. We categorized participants into four recovery phases according to the assessment time after surgery: acute phase (≤ 14 days after surgery, hospital stay), post-acute phase (15-42 days after surgery, mostly rehabilitation), extended recovery phase (43-182 days post-surgery, typically post-discharge at home), and long-term recovery phase (183-365 days post-surgery). All variables were reported descriptively for each phase using mean and standard deviation or median and 25th-75th percentile depending on their distribution. Results: We enrolled 564 PFF participants (66% women). The mean age was 77.5 (SD 9.6) years. Almost 90% of all participants (n = 505) had a valid digital mobility assessment (wear time of > 12 h per day and at least 3 valid days). DMO domains such as amount (e.g., number of steps), pace (e.g., walking speed), and pattern (bout distribution) demonstrated large differences across phases. Conclusions: The observed variation in walking amount and pace and pattern across recovery phases indicate that DMOs provide a granular analysis of real-world mobility of hip fracture survivors. When confirmed by longitudinal analyses, including results on minimal important differences, the use of selected DMOs will provide a novel approach for monitoring, predictive modelling, prognosis, stratification, and evaluation of clinical trials and hip fracture services., Open Access funding enabled and organized by Projekt DEAL. This study was part of the Mobilise-D project, which was funded by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD and LR were also supported by the IDEA-FAST project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853981.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cocreating the visualization of digital mobility outcomes: Delphi-type process with patients

  • Lumsdon, Jack
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Cantu, Alma
Background: Recent technological advances in wearable devices offer new potential for measuring mobility in real-world contexts. Mobilise-D has validated digital mobility outcomes to provide novel outcomes and end points in clinical research of 4 different long-term health conditions (Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, and proximal femoral fracture). These outcomes also provide unique information that is important to patients; however, there is limited literature that explores the optimal methods to achieve this, such as the best way to visualize patients' data. Objective: This study aimed to identify meaningful outcomes for each condition and how to best visualize them from the perspective of end users. Methods: Using a Delphi-type protocol with patients as subject matter experts, we gathered iterative feedback on the cocreation of visualizations through 3 rounds of questionnaires. An open-ended questionnaire was used in round 1 to understand what aspects of mobility were most influenced by their health condition. These responses were mapped onto relevant digital mobility outcomes and walking experiences and then prioritized for visualization. Using patient responses, we worked alongside researchers, clinicians, and a patient advisory group to develop visualizations that depicted a week of mobility data. During rounds 2 and 3, participants rated usefulness and ease of understanding on a 5-point Likert scale and provided unstructured feedback in comment boxes for each visualization. Visualizations were refined using the feedback from round 2 before receiving further feedback in round 3. Results: Participation varied across rounds 1 to 3 (n=48, n=79, and n=78, respectively). Round 1 identified important outcomes and contexts for each health condition, such as walking speed and stride length for people with Parkinson disease or multiple sclerosis and number of steps for people with chronic obstructive pulmonary disease or proximal femoral fracture. The consensus was not reached for any visualization reviewed in round 2 or 3. Feedback was generally positive, and some participants reported that they were able to understand the visualization and interpret what the visualization represented. Conclusions: Through the feedback provided and existing data visualization principles, we developed recommendations for future visualizations of mobility- and health-related data. Visualizations should be readable by ensuring that large and clear fonts are used and should be friendly for people with vision impairments, such as color blindness. Patients have a strong understanding of their own condition and its variability; hence, adding additional factors into visualizations is recommended to better reflect the nuances of a condition. Ensuring that outcomes and visualizations are meaningful requires close collaboration with patients throughout the development process., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU; grant agreement 820820). This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The content of the current publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, nor any associated partners are responsible for any use that may be made of the information contained herein. HG was supported by the Fraunhofer Internal Programs (grants Attract 044–602140 and 044–602150). HG also received institutional funding from the Deutsche Forschungsgemeinschaft (German Research Foundation)—SFB 1483—Project-ID 442419336, EmpkinS. LR, AY, and SDD were also supported by the IMI2 JU project IDEA-FAST (grant agreement 853981). LR, AY, and SDD were supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre based at The Newcastle upon Tyne Hospital National Health Service (NHS) Foundation Trust, Newcastle University, and the Cumbria, Northumberland, and Tyne and Wear NHS Foundation Trust and the NIHR/Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. LR received funding from the NIHR Senior Investigator Awards (2020-2024 and 2024-2028). EB was supported by the NIHR Sheffield Biomedical-Research Centre and Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the Department of Health and Social Care.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Construct validity of real-world digital mobility outcomes in patients after proximal femoral fracture: a cross-sectional observational study

  • Eckert, Tobias
  • de las Heras, Martí
  • Alvarez, Paula
  • Buekers, Joren
  • Koch, Sarah
  • García Aymerich, Judith
Digital mobility outcomes (DMOs) offer unique insights into recovery of real-world mobility after proximal femoral fracture (PFF), but their clinical validity remains to be established. This study assessed construct validity (convergent, divergent, and known-groups) of 24 DMOs measuring walking activity (amount, pattern) and gait (pace, rhythm, bout-to-bout variability) in patients within one year after PFF. Patients were recruited from inpatient and outpatient lists at five European sites, resulting in 505 included participants (66% female), with mean age of 77.6 ± 9.4 years and supervised gait speed of 0.7 ± 0.4 m/s. Mobility was monitored over seven days using a single wearable device on the lower back. Convergent and divergent validity analyses were stratified by two groups: acute (≤ 14 days since surgery) and non-acute (≥ 15 days since surgery). Correlations between DMOs and related (clinical- and patient-reported mobility outcomes) and unrelated constructs (hearing impairment and systolic blood pressure) were compared to a priori expected correlations. Known-groups validity was assessed across four recovery phases. The results were evaluated individually by experts and in a subsequent consensus meeting, with 17 of 24 DMOs showing evidence of construct validity in non-acute PFF patients. These findings represent an initial step in a larger process towards regulatory endorsement., This study is part of the Mobilise-D project, which was funded by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU received support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This work was also supported by the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre (NIHR203321). ISGlobal acknowledges support from the grant CEX2023-0001290-S funded by MCIN/AEI/ https://doi.org/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. MdlH was funded by European Union-NextGenerationEU, under the Program Investigo (INVESTIGO 2022, AGAUR- ref. BDNS 608313, file 2022 INV-1 00046 - Code 100046TC19). LR is supported by the IMI2 JU project IDEA-FAST (grant agreement 853981). LR is supported by the NIHR Newcastle Biomedical Research Centre based at The Newcastle upon Tyne Hospital National Health Service (NHS) Foundation Trust, Newcastle University, and the Cumbria, Northumberland, and Tyne and Wear NHS Foundation Trust and the NIHR/Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. LR received funding from the NIHR Senior Investigator Awards (2020-2024 and 2024-2028). Content in this publication reflects the authors¿ views and neither IMI nor the European Union, EFPIA, NHS, NIHR or the Department of Health and Social Care are responsible for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Assessing real-world gait with digital technology? Validation, insights and recommendations from the Mobilise-D consortium

  • Micó-Amigo, M. Encarna
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mobilise-D consortium
Background: Although digital mobility outcomes (DMOs) can be readily calculated from real-world data collected with wearable devices and ad-hoc algorithms, technical validation is still required. The aim of this paper is to comparatively assess and validate DMOs estimated using real-world gait data from six different cohorts, focusing on gait sequence detection, foot initial contact detection (ICD), cadence (CAD) and stride length (SL) estimates. Methods: Twenty healthy older adults, 20 people with Parkinson's disease, 20 with multiple sclerosis, 19 with proximal femoral fracture, 17 with chronic obstructive pulmonary disease and 12 with congestive heart failure were monitored for 2.5 h in the real-world, using a single wearable device worn on the lower back. A reference system combining inertial modules with distance sensors and pressure insoles was used for comparison of DMOs from the single wearable device. We assessed and validated three algorithms for gait sequence detection, four for ICD, three for CAD and four for SL by concurrently comparing their performances (e.g., accuracy, specificity, sensitivity, absolute and relative errors). Additionally, the effects of walking bout (WB) speed and duration on algorithm performance were investigated. Results: We identified two cohort-specific top performing algorithms for gait sequence detection and CAD, and a single best for ICD and SL. Best gait sequence detection algorithms showed good performances (sensitivity > 0.73, positive predictive values > 0.75, specificity > 0.95, accuracy > 0.94). ICD and CAD algorithms presented excellent results, with sensitivity > 0.79, positive predictive values > 0.89 and relative errors < 11% for ICD and < 8.5% for CAD. The best identified SL algorithm showed lower performances than other DMOs (absolute error < 0.21 m). Lower performances across all DMOs were found for the cohort with most severe gait impairments (proximal femoral fracture). Algorithms' performances were lower for short walking bouts; slower gait speeds (< 0.5 m/s) resulted in reduced performance of the CAD and SL algorithms. Conclusions: Overall, the identified algorithms enabled a robust estimation of key DMOs. Our findings showed that the choice of algorithm for estimation of gait sequence detection and CAD should be cohort-specific (e.g., slow walkers and with gait impairments). Short walking bout length and slow walking speed worsened algorithms' performances. Trial registration ISRCTN - 12246987., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant Agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD, LR, AY were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST—Grant Agreement 853981. LA, LR, AY and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. LA, LR, AY and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the National Institute for Health Research (NIHR) through the Sheffield Biomedical Research Centre (BRC, Grant Number IS-BRC-1215–20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and from the Generalitat de Catalunya through the CERCA Program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, NHS, NIHR, DHSC, or any associated partners are responsible for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Walking into aging: real-world mobility patterns and digital benchmarks from the InCHIANTI Study

  • Albites-Sanabria, Jose
  • Palumbo, Pierpaolo
  • Bandinelli, Stefania
  • D&apos;Ascanio, Ilaria
  • Mellone, Sabato
  • Paraschiv-Ionescu, Anisoara
  • Küderle, Arne
  • Cereatti, Andrea
  • Del Din, Silvia
  • Kluge, Felix
  • Gazit, Eran
  • Jansen, Carl-Philipp
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Rochester, Lynn
  • Klenk, Jochen
  • Ferrucci, Luigi
  • Becker, Clemens
  • Chiari, Lorenzo
  • Palmerini, Luca
Mobility is a cornerstone of health and quality of life, particularly in older adults. Digital mobility outcomes (DMOs) from real-world walking data offer crucial insights into the functional status and early markers of mobility decline. This study provides reference values for walking activity, pace, rhythm, and gait bout-to-bout variability in community-dwelling older adults and evaluates the effects of age, sex, height, and weight on these parameters. Using data from 200 older adults (aged 65-94 years) from the InCHIANTI Study and applying the Mobilise-D computational pipeline, we analyzed real-world walking over a week. Significant differences by sex and age were found, with males showing higher walking activity in younger age groups (65-74 and 75-84 years) but not in the oldest group (85-94 years). Additionally, we observed non-linear trends in mobility metrics with age, indicating an accelerated reduction in mobility at certain age ranges. These findings underscore the importance of monitoring real-world walking data to pinpoint critical periods of mobility decline and guide targeted interventions. This work offers valuable benchmarks for clinical assessments and future research., We want to acknowledge the participants who volunteered to take part in the clinical studies. Their contribution has been vital to the successful completion of the present study. The InCHIANTI baseline study (1998–2000) was supported as a “targeted project” (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336); the InCHIANTI follow-up study 1 (2001–2003) was funded by the U.S. National Institute on Aging (Contracts: N.1-AG[1]1-1 and N.1-AG-1-2111); the InCHIANTI follow-up study 4 and 5 were supported by the Agency for Regional Health Care of Tuscany (Reg. n° 586/R, 26/10/2012). This research was co-funded by the Italian Complementary National Plan PNC-I.1 Research initiatives for innovative technologies and pathways in the health and welfare sector” D.D. 931 of 06/06/2022, DARE - DigitAl lifelong pRevEntion initiative, code PNC0000002, CUP: B53C22006450001. The study has been funded in part by the European Union (Seventh Framework Program (FP7/2007-2013) under grant agreement No.: 288940 (FARSEEING project)), and by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820820 (Mobilise[1]D). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. S.D.D. was also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST - Grant Agreement 853981 and by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. S.D.D. was supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. S.D.D. was also supported by the UK Research and Innovation (UKRI) Engineering and Physical Sciences Research Council (EPSRC) (Grant Ref: EP/W031590/1, Grant Ref: EP/X031012/1 and Grant Ref: EP/X036146/1).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Digital assessment of real-world walking in people with impaired mobility: How many hours and days are needed?

  • Buekers, Joren
  • Koch, Sarah
  • Marchena, José
  • Lemos, Jorge
  • García Aymerich, Judith
Background: Impaired mobility increases falls and mortality risk. However, guidelines to reliably assess real-world walking activity and gait remain undefined. We aimed to (i) determine the minimum daily wear time during waking hours (7:00–22:00) for a valid measurement day, (ii) identify the minimum number of valid days, and (iii) weekend days, to reliably assess weekly walking activity and gait parameters, and (iv) provide recommendations for reliable real-world walking assessments. Methods: Participants with chronic obstructive pulmonary disease (n = 565), multiple sclerosis (n = 558), Parkinson’s disease (n = 543) or proximal femoral fracture (n = 487) from 10 countries were asked to wear a single wearable device on the lower back, 24 h/day for seven days, resulting in 13,191 measurement days. The Mobilise-D processing pipeline was used to obtain 24 daily walking activity and gait parameters. Minimum daily wear time was determined as the highest wear time category that did not statistically change parameter values. Intraclass correlation coefficients ≥ 0.80 determined the minimum number of valid measurement and weekend days. Results: The minimum daily wear time varied between “no requirement” (13% of parameter-condition combinations) and > 14 h (19%), with higher requirements for walking activity than gait parameters. The minimum number of days ranged from 1 (17%) to > 7 days (6%), and was higher for parameters that are yet to be clinically validated. There was no evidence of a weekend nor health condition effect on parameter reliability. Conclusions: For studies involving multiple walking activity and gait parameters or health conditions, expert consensus recommends a minimum of > 12 h of daily wear time across ≥ 3 days. For studies that involve specific parameters or health conditions, individual recommendations are provided within the manuscript. Supplementary Information: The online version contains supplementary material available at 10.1186/s12966-025-01851-3., This work was supported by the Mobilise-D project that received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Barcelona Institute for Global Health (ISGlobal) receives support from the grant CEX2023-0001290-S funded by MCIN/AEI/https://doi.org/10.13039/5011 00011033, and support from the Generalitat de Catalunya through the CERCA rogram. Joren Buekers (FJC2021-046458-I) and Sarah Koch (IJC2020-044363-I) received funding from the Juan de la Cierva Formación and Incorporación, respectively, financed by MICIU/AEI/https://doi.org/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. This paper presents independent research supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC), and the NIHR Sheffield BRC. The NIHR Newcastle BRC is a partnership between Newcastle Hospitals NHS Foundation Trust, Newcastle University, and Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust and is funded by the NIHR. The research was also supported by the NIHR Sheffield Biomedical Research Centre based at the Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield and carried out at the NIHR Sheffield Clinical Research Facility at the Sheffield Teaching Hospitals NHS Foundation Trust. LR, AY and SDD were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST - Grant Agreement 853981. LR, AY and SDD were supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust and, the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. SDD was supported by the UK Research and Innovation (UKRI) Engineering and Physical Sciences Research Council (EPSRC) (Grant Ref: EP/W031590/1, Grant Ref: EP/X031012/1 and Grant Ref: EP/X036146/1). AY is also supported by the Michael J Fox Foundation (grant references MJFF-022735 & MJFF-022737), UK Engineering and Physical Sciences Research Council (EPSRC), grant number EP/X036146/1, Intercept Pharmaceuticals, NIHR HTA (grant reference NIHR129175). She is in receipt of grants from Parkinson's UK, Weston Brain Institute, Dunhill Medical Trust and Cure Parkinson's Trust. HD is a post-doctoral researcher of FWO Flanders (12ZW822N). The views expressed are those of the authors and not necessarily those of the IMI, the European Union, the EFPIA, NHS, NIHR, the Department of Health and Social Care or any Associated Partners
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

  • Kirk, Cameron
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mobilise-D consortium
This study aimed to validate a wearable device's walking speed estimation pipeline, considering complexity, speed, and walking bout duration. The goal was to provide recommendations on the use of wearable devices for real-world mobility analysis. Participants with Parkinson's Disease, Multiple Sclerosis, Proximal Femoral Fracture, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, and healthy older adults (n = 97) were monitored in the laboratory and the real-world (2.5 h), using a lower back wearable device. Two walking speed estimation pipelines were validated across 4408/1298 (2.5 h/laboratory) detected walking bouts, compared to 4620/1365 bouts detected by a multi-sensor reference system. In the laboratory, the mean absolute error (MAE) and mean relative error (MRE) for walking speed estimation ranged from 0.06 to 0.12 m/s and - 2.1 to 14.4%, with ICCs (Intraclass correlation coefficients) between good (0.79) and excellent (0.91). Real-world MAE ranged from 0.09 to 0.13, MARE from 1.3 to 22.7%, with ICCs indicating moderate (0.57) to good (0.88) agreement. Lower errors were observed for cohorts without major gait impairments, less complex tasks, and longer walking bouts. The analytical pipelines demonstrated moderate to good accuracy in estimating walking speed. Accuracy depended on confounding factors, emphasizing the need for robust technical validation before clinical application.Trial registration: ISRCTN - 12246987., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD, LR, AY were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST—Grant Agreement 853981. LA, LR, AY and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. LA, LR, AY and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the National Institute for Health Research (NIHR) through the Sheffield Biomedical Research Centre (BRC, Grant Number IS-BRC-1215–20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and from the Generalitat de Catalunya through the CERCA Program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, NHS, NIHR, DHSC, or any associated partners are responsible for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evaluating the accuracy and reliability of real-world digital mobility outcomes in older adults after hip fracture: Cross-sectional observational study

  • Berge, Martin A.
  • García Aymerich, Judith
  • Koch, Sarah
  • Vereijken, Beatrix
Background: Algorithms estimating real-world digital mobility outcomes (DMOs) are increasingly validated in healthy adults and various disease cohorts. However, their accuracy and reliability in older adults after hip fracture, who often walk slowly for short durations, is underexplored. Objective: This study examined DMO accuracy and reliability in a hip fracture cohort considering walking bout (WB) duration, physical function, days since surgery, and walking aid use. Methods: In total, 19 community-dwelling participants were real-world monitored for 2.5 hours using a lower back wearable device and a reference system combining inertial modules, distance sensors, and pressure insoles. A total of 6 DMO estimates from 164 WBs from 58% (11/19) of the participants (aged 71-90 years; assessed 32-390 days after surgery; Short Physical Performance Battery [SPPB] scores of 3-12; gait speed range 0.39-1.34 m/s) were assessed against the reference system at the WB and participant level. We stratified by WB duration (all WBs, WBs of >10 seconds, WBs of 10-30 seconds, and WBs of >30 seconds) and lower versus higher SPPB scores and observed whether days since surgery and walking aid use affected DMO accuracy and reliability. Results: Across WBs, walking speed and distance ranged from 0.25 to 1.29 m/s and from 1.7 to 436.5 m, respectively. Estimation of walking speed, cadence, stride duration, number of steps, and distance stratified by WB duration showed intraclass correlation coefficients (ICCs) ranging from 0.50 to 0.99 and mean relative errors (MREs) from -6.9% to 12.8%. Stride length estimation showed poor reliability, with ICCs ranging from 0.30 to 0.49 and MREs from 6.1% to 13.2%. Walking speed and distance ICCs in the higher-SPPB score group ranged from 0.85 to 0.99, and MREs ranged from -10.1% to -1.7%. In the lower-SPPB score group, walking speed and distance ICCs ranged from 0.17 to 0.99, and MREs ranged from 13.5% to 32.6%. There was no discernible effect of time since surgery or walking aid use. Conclusions: In total, 5 accurate and reliable real-world DMOs were identified in older adults after hip fracture: walking speed, cadence, stride duration, number of steps, and distance. Accuracy and reliability of most DMOs improved when excluding WBs of <10 seconds and were higher for WBs of >30 seconds than for WBs of 10 to 30 seconds and for participants with higher physical function. DMOs capture daily gait as early as 1 month after surgery also in people using walking aids. However, as most WBs in this cohort were short, there was a trade-off between improving accuracy and reliability by excluding short WBs and losing a substantial amount of data. These results have important implications for establishing the clinical validity of DMOs and evaluating the effects of interventions on daily-life gait, thereby facilitating the design of optimal care pathways., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. The authors thank the Mobilise-D technical validation study team of work package 2, all participants who devoted their time and energy to this taxing protocol in times of COVID-19, and Miriam Dinger at the Robert Bosch Foundation for Medical Research and Dr Tim Klüter at University Hospital Schleswig-Holstein for their indispensable help in recruiting patients. MAB acknowledges ChatGPT, an artificial intelligence model by OpenAI, for suggestions that helped improve the clarity of some sentences in this paper. SDD and LR were also supported by the Identifying Digital Endpoints to Assess Fatigue, Sleep, and Activities in Daily Living in Neurodegenerative Disorders and Immune-Mediated Inflammatory Diseases project that has received funding from the IMI 2 Joint Undertaking under grant agreement 853981. LR is a National Institute for Health and Care Research (NIHR) senior investigator. Both SDD and LR were supported by the NIHR Newcastle Biomedical Research Centre based at the Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust; Newcastle University; and the Cumbria, Northumberland, Tyne, and Wear NHS Foundation Trust. SDD and LR were also supported by the NIHR and Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. SDD was supported by the UK Research and Innovation Engineering and Physical Sciences Research Council (grant reference EP/X031012/1 and EP/X036146/1). The Barcelona Institute for Global Health acknowledges support from grant CEX2018-000806-S funded by the Ministry of Science, Innovation, and Universities and the State Research Agency (MCIN/AEI/10.13039/501100011033) and support from the Government of Catalonia through the Research Centers of Catalonia program. The views expressed in this publication are those of the authors and do not necessarily reflect those of the IMI, the European Union, the European Federation of Pharmaceutical Industries and Associations, any associated partners, the NIHR, or the Department of Health and Social Care, who are not responsible for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform

  • Palmqvist, Sebastian
  • Anastasi, Federica
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, Jose
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden (n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93-0.96. In secondary care, the accuracies were 89-91%, the positive predictive values 89-95% and the negative predictive values 77-90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92-94% in secondary and primary care, excluding 12-17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations., We would like to express our gratitude to the participants, and relatives, in all studies, without whom this research would have not been possible. In addition, we thank B. Arslan for analyzing plasma Aβ in the Gothenburg cohort. The BioFINDER group was supported by the National Institute of Aging (grant no. R01AG083740 to O.H., S.P., R.O. and S.J.), Alzheimer’s Association (grant nos. SG-23-1061717 and ZEN24-1069572 to O.H.), GHR Foundation (O.H. and S.P.), European Research Council (ERC, grant no. ADG-101096455 to O.H.), Swedish Research Council (grant nos. 2023-00356 to O.H., 2021-02219 to N.M.-C. and 2018-02052 to S.P.), ERA PerMed (grant no. ERAPERMED2021-184 to O.H.), the Knut and Alice Wallenberg Foundation (grant no. 2022-0231 to O.H.), the European Union’s (EU’s) Horizon Europe research and innovation program under grant agreement no. 101053962 (to O.H.), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University (to O.H.), the Swedish Alzheimer Foundation (grant nos. AF-1011949 and AF-994075 to S.P., AF-994229 to N.M.-C. and AF-981132 to S.P.), the Swedish Brain Foundation (grant nos. FO2023-0163 to N.M.-C., FO2024-0284 and FO2022-0204 to S.P. and FO2021-0293 to O.H.), the family Rönström’s Foundation (grant nos. FRS-0003 to N.M.-C. and FRS-0004 and FRS-0011 to S.P.), the Berg Family Foundation (O.H.), the Parkinson Foundation of Sweden (grant no. 1412/22 to O.H.), the Cure Alzheimer’s fund (O.H.), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (O.H.), the Skåne University Hospital Foundation (grant no. 2020-O000028 to S.P.), EU Joint Programme Neurodegenerative Diseases (grant no. 2019-03401 to N.M.-C.), WASP and DDLS Joint call for research projects (grant no. WASP/DDLS22-066 to N.M.-C.), Regionalt Forskningsstöd (grant no. 2022-1346 to S.P.) and the Swedish Federal Government under the ALF-agreement (grant nos. 2022-Projekt0107 to N.M.-C., 2022-Projekt0080 to O.H. and 2018-Projekt0226 to S.P.). The precursor of [18F]flutemetamol was sponsored by GE Healthcare. For the Gothenburg group, S.K. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (nos. ALFGBG-1005471, ALFGBG-965923, ALFGBG-81392 and ALFGBG-771071), the Alzheimerfonden (grant nos. AF-842471, AF-737641, AF-929959 and AF-939825), the Swedish Research Council (grant nos. 2019-02075 and 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden and the Swedish Brain Foundation (grant no. FO2024-0097). A.D. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant no. ALFGBG-984092). H.Z. is a Wallenberg Scholar and a distinguished professor at the Swedish Research Council. K.B. is supported by the Swedish Research Council (grant nos. 2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (grant nos. AF-930351, AF-939721, AF-968270 and AF-994551), Hjärnfonden, Sweden (grant nos. ALZ2022-0006, FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant nos. ALFGBG-965240 and ALFGBG-1006418), the Alzheimer’s Association 2022–2025 (grant no. SG-23-1038904 QC), the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden and an anonymous philanthropist and donor. The Barcelona group thanks P. Ortiz-Romero, M. de Diego, E. Jiménez, J. Torres and M. del Campo for technical support. F.A. received funding from grant no. JDC2022-049347-I, funded by the MCIU/AEI/10.13039/501100011033 and the EU NextGeneration EU/PRTR. M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001; project PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)). For the Brescia group, A. Pilotto has beensupported by grants of Airalzh Foundation AGYR2021) Life-BIO grant, the LIMPE-DISMOV Foundation Segala Grant 2021, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. V.Q. was supported by the H2020 IMI IDEA-FAST (grant no. ID853981). C.T. was supported by the PRIN 2021 RePlast (grant no. 20202THZAW). A. Padovani has been supported by grants of the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209, RF-2019 RF-2019-12369272 and PNRR-Health PNRR-MAD-2022-12376110. The funders had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review or approval of the paper and decision to submit the paper for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Laboratory and free-living gait performance in adults with COPD and healthy controls

  • Buekers, Joren
  • Koch, Sarah
  • García Aymerich, Judith
Background: Gait characteristics are important risk factors for falls, hospitalisations and mortality in older adults, but the impact of COPD on gait performance remains unclear. We aimed to identify differences in gait characteristics between adults with COPD and healthy age-matched controls during 1) laboratory tests that included complex movements and obstacles, 2) simulated daily-life activities (supervised) and 3) free-living daily-life activities (unsupervised). Methods: This case-control study used a multi-sensor wearable system (INDIP) to obtain seven gait characteristics for each walking bout performed by adults with mild-to-severe COPD (n=17; forced expiratory volume in 1 s 57±19% predicted) and controls (n=20) during laboratory tests, and during simulated and free-living daily-life activities. Gait characteristics were compared between adults with COPD and healthy controls for all walking bouts combined, and for shorter (≤30 s) and longer (>30 s) walking bouts separately. Results: Slower walking speed (-11 cm·s-1, 95% CI: -20 to -3) and lower cadence (-6.6 steps·min-1, 95% CI: -12.3 to -0.9) were recorded in adults with COPD compared to healthy controls during longer (>30 s) free-living walking bouts, but not during shorter (≤30 s) walking bouts in either laboratory or free-living settings. Double support duration and gait variability measures were generally comparable between the two groups. Conclusion: Gait impairment of adults with mild-to-severe COPD mainly manifests during relatively long walking bouts (>30 s) in free-living conditions. Future research should determine the underlying mechanism(s) of this impairment to facilitate the development of interventions that can improve free-living gait performance in adults with COPD., Support statement: This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 820820. This JU receives support from the European Union's Horizon 2020 research and innovation programme, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). S. Del Din and L. Rochester were also supported by the Innovative Medicines Initiative 2 (IMI2) JU project IDEA-FAST – grant agreement 853981. S. Del Din, L. Alcock and L. Rochester were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust, and by the NIHR/Welcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. C. Mazzà and E. Buckley were also supported by the Sheffield BRC based at the Sheffield Teaching Hospital and the University of Sheffield. H. Demeyer is a post-doctoral research fellow of the Flemish Research Foundation (FWO Flanders). The Barcelona Institute for Global Health (ISGlobal) receives support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” Programme (CEX 2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Programme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, the IMI, the European Union, the EFPIA or any Associated Partners. Funding information for this article has been deposited with the Crossref Funder Registry.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Real-World gait detection using a wrist-worn inertial sensor: Validation study

  • Kluge, Felix
  • Buekers, Joren
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mueller, Arne
Background: Wrist-worn inertial sensors are used in digital health for evaluating mobility in real-world environments. Preceding the estimation of spatiotemporal gait parameters within long-term recordings, gait detection is an important step to identify regions of interest where gait occurs, which requires robust algorithms due to the complexity of arm movements. While algorithms exist for other sensor positions, a comparative validation of algorithms applied to the wrist position on real-world data sets across different disease populations is missing. Furthermore, gait detection performance differences between the wrist and lower back position have not yet been explored but could yield valuable information regarding sensor position choice in clinical studies. Objective: The aim of this study was to validate gait sequence (GS) detection algorithms developed for the wrist position against reference data acquired in a real-world context. In addition, this study aimed to compare the performance of algorithms applied to the wrist position to those applied to lower back-worn inertial sensors. Methods: Participants with Parkinson disease, multiple sclerosis, proximal femoral fracture (hip fracture recovery), chronic obstructive pulmonary disease, and congestive heart failure and healthy older adults (N=83) were monitored for 2.5 hours in the real-world using inertial sensors on the wrist, lower back, and feet including pressure insoles and infrared distance sensors as reference. In total, 10 algorithms for wrist-based gait detection were validated against a multisensor reference system and compared to gait detection performance using lower back-worn inertial sensors. Results: The best-performing GS detection algorithm for the wrist showed a mean (per disease group) sensitivity ranging between 0.55 (SD 0.29) and 0.81 (SD 0.09) and a mean (per disease group) specificity ranging between 0.95 (SD 0.06) and 0.98 (SD 0.02). The mean relative absolute error of estimated walking time ranged between 8.9% (SD 7.1%) and 32.7% (SD 19.2%) per disease group for this algorithm as compared to the reference system. Gait detection performance from the best algorithm applied to the wrist inertial sensors was lower than for the best algorithms applied to the lower back, which yielded mean sensitivity between 0.71 (SD 0.12) and 0.91 (SD 0.04), mean specificity between 0.96 (SD 0.03) and 0.99 (SD 0.01), and a mean relative absolute error of estimated walking time between 6.3% (SD 5.4%) and 23.5% (SD 13%). Performance was lower in disease groups with major gait impairments (eg, patients recovering from hip fracture) and for patients using bilateral walking aids. Conclusions: Algorithms applied to the wrist position can detect GSs with high performance in real-world environments. Those periods of interest in real-world recordings can facilitate gait parameter extraction and allow the quantification of gait duration distribution in everyday life. Our findings allow taking informed decisions on alternative positions for gait recording in clinical studies and public health. Trial registration: ISRCTN Registry 12246987; https://www.isrctn.com/ISRCTN12246987. International registered report identifier (irrid): RR2-10.1136/bmjopen-2021-050785., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU; grant 820820). The IMI2 JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. SDD, LR, and AY were also supported by the IMI2 JU project Identifying Digital Endpoints to Assess Fatigue, Sleep and Activities in Daily Living (grant 853981). LA, LR, AY, and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust. JMH and YEB are supported in part by the National Institutes of Health (grant R01AG79133). LA, LR, AY, and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility infrastructure at The Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the NIHR through the Sheffield BRC (grant IS-BRC-1215-20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” program (CEX2018-000806-S) and from the Generalitat de Catalunya through the Centres de Recerca de Catalunya program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither Innovative Medicines Initiative nor the European Union, European Federation of Pharmaceutical Industries and Associations, National Health Service, NIHR, Department of Health and Social Care, or any associated partners are responsible for any use that may be made of the information contained herein.